X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer

Yuvraj_pawp by Yuvraj_pawp
15th September 2014
in Research & Development

Array BioPharma Inc. a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients with cancer, today announced the appointment of Victor Sandor, M.D., as Chief Medical Officer.  Dr. Sandor will be responsible for leading clinical, medical and regulatory strategy and operations across the Array portfolio, including binimetinib, a MEK inhibitor in Phase 3 trials for ovarian cancer and melanoma, and filanesib, a KSP inhibitor for multiple myeloma.  Dr. Sandor brings a wealth of experience in oncology/hematology drug development, following a successful track record in leadership positions at premier biopharmaceutical and pharmaceutical companies, including Incyte, Biogen, and AstraZeneca.  In these roles, he was instrumental in bringing products such as Jakafi® (ruxolitinib), Arimidex® (anastrozole) and Faslodex® (fulvestrant injection) to the market and was responsible for advancing these and several other targeted-and immuno-therapies through clinical development for a broad range of cancer indications.

“Dr. Sandor’s leadership, experience and vision will strengthen our clinical development efforts as we advance our late-stage, wholly-owned assets toward commercialization,” said Ron Squarer, Chief Executive Officer, Array BioPharma.  “With the possible near-term return of binimetinib to Array, his expertise will have significant impact on our long-term success.”

“I am pleased to join the Array team at such an exciting time in the company’s evolution,” said Dr. Sandor. “In addition to the impressive portfolio of clinical-stage assets in development by Array’s partners, I look forward to focusing on the development of binimetinib and filanesib, which each target patient populations with significant unmet medical need.”

Dr. Sandor has more than a decade of experience in the pharmaceutical and biotechnology industries.  Prior to joining Array, he was Senior Vice President for Global Clinical Development at Incyte Corporation.  In this role, he was instrumental in the development, approval and commercialization of the first JAK inhibitor, while leading clinical development, clinical operations,  medical affairs and biostatistics across the entire portfolio including responsibility for several novel mechanisms including PI3K, c-Met and IDO1 inhibitors. Prior to Incyte, Dr. Sandor was Vice President and Chief Medical Officer for oncology at Biogen Idec.  He previously held positions of increasing responsibility in oncology product development at AstraZeneca, where he played an important role in the registration of Arimidex for adjuvant use, the development of Faslodex, and the development of several early stage programs through proof of concept.  Dr. Sandor received his MD CM from McGill University in Montreal, Canada, and completed his Fellowship in Medical Oncology at the National Institutes of Health in Bethesda, Maryland.

Dr. Sandor will replace Array’s prior Chief Medical Officer, Michael Needle, M.D., who is leaving the company to pursue other opportunities.

Previous Post

Takeda and Lundbeck announce FDA approval of Brintellix™

Next Post

INDUSTRY NEWS Hayat Pharmacy to open Greenfield location

Related Posts

News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
Report Indicates UK £62bn Behind In Global R&D Investment
News

Report Indicates UK £62bn Behind In Global R&D Investment

3rd November 2022
News

Once More, M&As In Biotechechnology Industry Are Thriving

2nd November 2022
DNA
News

Ancient Viral DNA Guards Against Infections In Human Genome

31st October 2022
News

Omicron Subvariants Withstand Essential Antibody Treatments

31st October 2022
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits
News

Research And Development In UK Falls Behind Other Nations

28th October 2022
Next Post

INDUSTRY NEWS Hayat Pharmacy to open Greenfield location

Latest News

FDA Approvals

NHS Acquires Potentially Lifesaving Breast Cancer Medication

9th November 2022
Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

9th November 2022
Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In